Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -154.47% is 103% below its 5-year average of -75.91%, near the low end of its 5-year range (-154.47%–-25.09%).
26.78% below its 12-month average of -121.84%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -18.43%.
RETURN ON ASSETS (ROA)
-154.47%
RETURN ON ASSETS (ROA) AVG TTM
-121.84%
RETURN ON ASSETS (ROA) AVG 3Y
-88.87%
RETURN ON ASSETS (ROA) AVG 5Y
-75.91%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-26.78%
CURRENT VS 3Y AVG
-73.82%
CURRENT VS 5Y AVG
-103.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 853 covered companies
CURRENT VS SECTOR MEDIAN
-379.13%
vs the sector median at left
iSpecimen Inc.
Market Cap
$2.77M
Return on Assets (ROA)
-154.47%
TTM Avg
-121.84%
3Y Avg
-88.87%
5Y Avg
-75.91%
Market Cap
$2.84M
Return on Assets (ROA)
-5.30%
TTM Avg
-9.07%
3Y Avg
-11.09%
5Y Avg
-0.33%
Market Cap
$2.62M
Return on Assets (ROA)
-121.85%
TTM Avg
-199.78%
3Y Avg
-166.32%
5Y Avg
-134.78%
Market Cap
$2.54M
Return on Assets (ROA)
-199.30%
TTM Avg
-137.41%
3Y Avg
-109.57%
5Y Avg
-977.62%
Market Cap
$3.01M
Return on Assets (ROA)
-238.27%
TTM Avg
-211.11%
3Y Avg
-146.32%
5Y Avg
-173.65%
Market Cap
$2.50M
Return on Assets (ROA)
-228.77%
TTM Avg
-130.86%
3Y Avg
-126.84%
5Y Avg
-140.90%
Market Cap
$3.04M
Return on Assets (ROA)
-80.08%
TTM Avg
-84.48%
3Y Avg
-250.02%
5Y Avg
-187.49%
Market Cap
$3.06M
Return on Assets (ROA)
-86.02%
TTM Avg
-152.03%
3Y Avg
-125.45%
5Y Avg
-181.83%
Market Cap
$2.47M
Return on Assets (ROA)
-107.18%
TTM Avg
-105.74%
3Y Avg
-98.21%
5Y Avg
-95.08%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iSpecimen Inc. (ISPC) | $2.77M | -154.47% | -121.84% | -88.87% | -75.91% |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.84M | -5.30% | -9.07% | -11.09% | -0.33% |
| Nuwellis, Inc. (NUWE)vs › | $2.62M | -121.85% | -199.78% | -166.32% | -134.78% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -199.30% | -137.41% | -109.57% | -977.62% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.01M | -238.27% | -211.11% | -146.32% | -173.65% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.50M | -228.77% | -130.86% | -126.84% | -140.90% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.04M | -80.08% | -84.48% | -250.02% | -187.49% |
| Revelation Biosciences, Inc. (REVB)vs › | $3.06M | -86.02% | -152.03% | -125.45% | -181.83% |
| Jaguar Health, Inc. (JAGX)vs › | $2.47M | -107.18% | -105.74% | -98.21% | -95.08% |
| IceCure Medical Ltd (ICCM)vs › | $3.12M | -95.33% | -115.11% | -93.94% | -73.81% |
ROA
-154.5%
ROE
-657.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -110.03% |
| 2024-12-31 | -133.66% |
| 2023-12-31 | -70.16% |
| 2022-12-31 | -41.62% |
| 2021-12-31 | -25.09% |
| 2020-12-31 | -74.92% |
| 2019-12-31 | -112.16% |
| 2018-12-31 | -132.20% |
